Skip to content

#综述/观点

Today 2 items
TodayOct 16Fri
  1. statnews.com45

    Mass. lawmaker Auchincloss favors boosting U.S. biotech over targeting China

    Rep. Jake Auchincloss (D-Mass.) told the STAT Summit in Boston that Congress should invest in domestic biotech rather than rely on protectionist policies against China, which he said hurts U.S. competitiveness. He plans to introduce a bill modeled on Australia's system, letting early-phase trials bypass pre-approval evaluation by the national regulator to speed U.S. research. He also criticized the FDA's National Priority Voucher program and OMB proposals to override peer review, and backed cracking down on PBM practices and reforming 340B.

Oct 15Thu
  2. statnews.com52

    Opinion: MyChart said I could opt out of sharing my health data. Figuring out how was maddening

    A STAT News investigation co-published with CalMatters and The Markup describes how patients who try to opt out of health data sharing face obstacles that make opting out nearly impossible. Testing 25 clinics and hospitals across seven states, the author found one Ohio hospital required 26 steps, a notary and a flight to Las Vegas to opt out, and that Phreesia mislabeled an optional data authorization as "Required" for 81 days before admitting no consent existed. Hospital systems including University Hospitals in Westlake use Epic's MyChart and Care Everywhere to share records, and after complaints to HHS and NPR coverage, Phreesia changed its form labeling.

    Why it matters: Documents systemic barriers that block patients from opting out of health data sharing at major hospital systems.

  3. statnews.com65

    Forty percent of high school students report binge eating in new CDC survey

    About 40% of U.S. high school students reported binge eating in the past month in the CDC's Youth Risk Behavior Survey, the first time the biennial survey has asked about it and its first disordered eating data in a decade. Of nearly 7,000 students, 17% reported binge eating within the last three days, with higher rates among female (19%) than male (16%) students and among Hispanic (20%), multiracial (20%) and Black (19%) students than white (15%). Advocacy groups now want questions on fasting, dieting and purging added.

    Why it matters: First CDC youth survey data on binge eating in a decade shows high prevalence with racial disparities.

  4. medicalxpress.com41

    Rise in private testosterone prescribing risks overtreatment and more strain on the NHS

    Stephen Atkin and Eric Kilpatrick warn in The BMJ that rapid growth in private testosterone prescribing in the UK risks overtreatment of men with nonspecific symptoms and shifts long-term monitoring costs onto the NHS. The UK testosterone replacement market was valued at about $205 million in 2024 and is projected to reach $365 million by 2032, with NHS community dispensing up 52% from 2020/21 to 2024/25 and subscription clinics charging £100–£375 a month. The authors call for national data and a reporting framework for private prescribers covering indications, patient numbers, monitoring and transfers of care.

  5. statnews.com54

    Former FDA officials blast DOGE as ‘one of the biggest disasters in American history’

    Former FDA commissioners Rob Califf, Scott Gottlieb and Ned Sharpless criticized DOGE at the STAT Summit, calling the Musk-led initiative's cuts of 3,500 workers "one of the biggest disasters in American history" and saying the resulting loss of institutional knowledge will take years to rebuild. Marty Makary resigned as commissioner in May, and White House official Heidi Overton has been nominated to replace him but has not faced a Senate confirmation vote. The ex-officials said acting commissioner Kyle Diamantas and policy lead Grace Graham are restoring rational decision-making, and advised Overton to recruit, support and defend the workforce if confirmed.

  6. statnews.com65

    As White House shifts focus toward AI and tech, U.S. science leaders defend role of the American university

    MIT enrolled nearly 500 fewer graduate students this fall, a 20% drop from 2024, after a $100 million cut in federal research awards, President Sally Kornbluth said at the STAT Summit in Boston. She and Science journals editor-in-chief Holden Thorp defended the 80-year-old model of federally funded university research as the Trump administration shifts priorities toward AI and technology, backed by $6 billion in new national research investments. Forecasts put China on track to surpass U.S. research spending in two to three years, with nine of the top 10 Nature Index institutions now in China.

    Why it matters: Federal funding cuts are shrinking U.S. graduate admissions while the administration redirects research dollars toward industry.

  7. nature.com56

    Editorial Expression of Concern: Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function

    Nature Medicine editors issued an Editorial Expression of Concern on 14 October 2026 about a 2017 paper reporting that thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function. The concerns involve similar-looking blots in Figs. 3n and 4a and overlapping images in Fig. 5e. Authors located one correct blot and replicated Fig. 5e data, but could not locate the original data for Fig. 4a; several authors agree with the expression, Farida Ahangari does not, and the rest have not responded.

    Why it matters: Editors flag image concerns in a widely cited fibrosis paper and warn readers to interpret its data with caution.

Oct 14Wed
  1. nature.com50

    Nature Index reveals the four countries to watch in biomedical engineering

    Nature Index data show biomedical-engineering papers grew 70% between 2021 and 2025, with China's share of global output rising from 28.9% to 50.9%, while the United States and Germany held second and third place. Four other leading countries show distinct patterns: South Korea ranks fourth through high specialization at 4.8% of its output; Canada's Share rose almost 60%, aided partly by a Can$2.2 billion life-sciences funding strategy; Switzerland's Share rose 19% to 49.2 with strong private-sector involvement; and the Netherlands grew modestly with international networks.

  2. medicalxpress.com46

    Long-term viral hepatitis control and changing patterns of liver cancer mortality in Japan

    A Hiroshima University review published in The Lancet Regional Health-Western Pacific finds that decades of national viral hepatitis control in Japan cut HBV and HCV prevalence sharply and reduced hepatocellular carcinoma mortality. HBsAg prevalence among first-time blood donors fell from 0.63% in 1995-2000 to 0.13% in 2017-2021, and the share of HCC deaths from nonviral causes rose from 6.8% in 1992 to 56.0% in 2019. The authors identify remaining gaps, including hepatitis in PWID, MSM, migrant and incarcerated populations, as Japan works toward the WHO 2030 elimination targets, and offer transferable lessons for other countries.

  3. nature.com40

    China’s extraordinary rise in science and how it will change the world

    China has become a global scientific powerhouse and in 2024 overtook the United States as the world's largest spender on gross domestic expenditure on R&D when adjusted for purchasing power parity, according to OECD figures. President Xi Jinping urged stronger fundamental research at an April Shanghai meeting, and the latest five-year plan targets frontier technologies such as AI, quantum applications and controlled nuclear fusion by 2030, with R&D spending to grow at least 7% per year through 2030. In 1978 China published fewer than 120 scientific articles internationally, or 0.02% of the global total, but systemic concerns remain, including scientific misconduct and trial-related deaths.

  4. biospace.com46

    European biotech leaders split on US-China fight for deal dominance, survey finds

    A BIO-Europe survey of 81 European biotech leaders, published Oct. 7, found no consensus on the top source of future innovation partnerships: 29 respondents picked the U.S., 24 picked China and 11 picked Europe. Europe received a "middling" score as a dealmaking hub, with capital availability named the biggest barrier to deals by 34 respondents and access to capital the top challenge to solve, cited by 42. Almost 80% blamed investor risk aversion for restricting investment.

  5. biospace.com48

    Alnylam bulls and bears fight it out after business-shaking guidance cut

    Alnylam cut full-year guidance by about $200 million after second-quarter sales of the TTR silencer Amvuttra in transthyretin-mediated amyloidosis fell short, and its stock has dropped from near $500 to around $250. Analysts at Guggenheim question whether the ATTR-CM opportunity is smaller than expected or whether stabilizers from Pfizer and BridgeBio are becoming preferred, while TD Cowen reiterated a $482 target and BMO argues the cut reflects second-line patient exhaustion. Alnylam is running Phase 3 trials of nucresiran in ATTR-CM and ATTR-PN, and a Phase 3 cardiovascular outcomes trial of zilebesiran in hypertension.

  6. nature.com46

    Can GLP-1s heal the brain? Obesity drugs get a makeover for addiction and depression

    Eli Lilly presented the first clinical results of brenipatide, a GLP-1 and GIP mimic related to tirzepatide, for alcohol use disorder at the Psych Congress in New Orleans; its half-life is 9–12 days versus 5–7 days for approved GLP-1 drugs. Kariya Pharmaceuticals shared early clinical results of the GLP-1 compound KP405 for Parkinson's disease, and Baseline Therapeutics plans phase III trials of BT-001 for alcohol use disorder starting in early 2027. Academic trials, including a 2025 semaglutide study in alcohol use disorder, have shown reduced craving and heavy drinking, encouraging industry interest in GLP-1 therapies for addiction and other brain disorders.

  7. jamanetwork.com40

    Arginine Treatment and Sickle Cell Disease Pain—A Great STArT, but a Hard End Point

    JAMA commentary discusses arginine as a candidate targeted treatment for sickle cell disease pain crises, which drive more than 70,000 pediatric emergency department visits annually in the US. Current care still relies on intravenous opioids, NSAIDs and fluids, with nearly 30% of discharged patients returning within days and similar readmission rates within 30 days. The piece frames the STArT trial as a starting point toward a treatment addressing vaso-occlusion.

  8. jamanetwork.com73

    From Biological Insight to a New Class of Medicines for Hemophilia A

    The 2026 Lasker-DeBakey Clinical Medical Research Award recognizes researchers who developed a bispecific antibody mimicking blood coagulation factor VIII. The antibody offers a new class of medicines for hemophilia A, a life-threatening bleeding disorder caused by lack of factor VIII. The winners describe how biological insight drove the drug's development.

    Why it matters: Lasker award spotlights a bispecific antibody that created a new treatment class for hemophilia A.

  9. jamanetwork.com77

    The 2026 Albert Lasker Basic Medical Research Award

    Emmanuel Mignot and Masashi Yanagisawa, winners of the 2026 Albert Lasker Basic Medical Research Award, identified the brain peptide orexin and established its role in sleep regulation. Their work linked orexin deficiency to narcolepsy. The Perspective traces how the discovery advanced understanding of the sleep disorder.

    Why it matters: Lasker Award honors the discovery of orexin and its link to narcolepsy.

Oct 13Tue
  1. Nat Biotechnol40

    Ten years, tens of millions of cells.

    The Human Cell Atlas consortium, launched in October 2016 by around 100 researchers led by Aviv Regev and Sarah Teichmann to map the body's roughly 30 trillion cells, has grown into one of the largest collaborative efforts in biology. By 2024 it had released four integrated v1 atlases, including a Human Lung Cell Atlas with over 2 million cells from 486 individuals across 49 datasets. Its next stage, cataloguing billions of cells, will draw on spatial biology and AI advances.

  2. thelancet.com40

    [Comment] Hepatitis C—is discrimination preventing elimination?

    The UK, driven chiefly by England and Scotland, is expected to be the first country to meet WHO's goal of eliminating hepatitis C virus infection by 2030. UK Health Security Agency analysis of NHS progress, published in April, 2026, showed that 84·6% of people living with HCV had been diagnosed and prevalence in people who inject drugs had fallen to 5·2% in 2024, with estimated incidence of 4·4 infections per 100 person-years, predicted to fall below WHO's target of two infections per 100 patient-years by 2030. The Lancet commentary asks whether discrimination is preventing elimination.

  3. nature.com69

    Engrafting human cortical organoids

    Kaganovsky and colleagues, writing in Nature, describe xenocortication, a method for integrating human cortical organoids into the mouse brain. They transplanted human iPSC-derived cortical organoids into the cortical cavity of neonatal immunodeficient apallial mice, in which most of the neocortex and hippocampus had been genetically depleted. MRI showed the grafts grew approximately 4.7-fold between 2 and 3 months after transplantation and made up nearly 92% of the combined cortical tissue volume.

    Why it matters: The graft growth data show a new route to larger, better integrated human brain organoid models in rodents.

Oct 12Mon
  1. Lancet52

    Strengthening health systems to prioritise, provide care, and prevent osteoarthritis: a roadmap for global health policy.

    A Lancet roadmap sets three strategic priorities for global osteoarthritis prevention and care: building national surveillance and embedding musculoskeletal health in health policies; scaling up person-centred care for approximately 600 million people living with the disease; and primary and secondary prevention targeting excess bodyweight and joint injury. By 2050, almost 1 billion people are expected to have osteoarthritis. The roadmap, aimed at policy makers, health services managers, clinicians and civil society organisations, calls for global collaboration beyond the UN's Agenda 2030 targets.

    Why it matters: Sets a concrete global policy agenda for a disease projected to affect 1 billion people by 2050.

  2. biopharmadive.com56

    Pharma’s $500B patent problem will come in waves — not as a cliff

    Evaluate forecasting data from Norstella show more than $500 billion in worldwide prescription drug sales at risk from generic competition between 2026 and 2032, with the largest single-year exposure of $158 billion in 2031. Merck is most exposed near term as Keytruda nears expiry in 2028, a year with $99 billion in sales at risk, while AbbVie faces roughly $50 billion of exposure in 2032 when Rinvoq and Skyrizi lose protection. Patent-exposed companies have responded with dealmaking since the start of 2024, led by Merck's six deals totalling $30.9 billion and Lilly's $27.2 billion across nine.

    Why it matters: Quantifies the multiyear patent-expiry risk facing major drugmakers and the dealmaking it is already driving.

  4. thelancet.com55

    [Health Policy] Strengthening health systems to prioritise, provide care, and prevent osteoarthritis: a roadmap for global health policy

    The Lancet outlines a roadmap for global health policy on osteoarthritis, projecting that by 2050 almost 1 billion people will live with the condition, which currently has no cure. It argues that osteoarthritis remains largely invisible in national and global health agendas and poorly integrated into chronic care service models. The roadmap calls for strengthening health systems to prioritise, provide care for, and prevent the disease.

    Why it matters: Sets out a global policy roadmap for a condition projected to affect almost 1 billion people by 2050.

Oct 11Sun
  1. Lancet40

    Migraine.

    Migraine is a chronic neurovascular disorder marked by recurrent moderate-to-severe head pain with disabling symptoms including aura, nausea, vomiting, phonophobia and photophobia. Its pathogenesis involves genetic and epigenetic factors across complex neurosensory and neurovascular networks. Decades of research have driven mechanism-based therapies that are transforming clinical practice and improving patients' lives.

    Why it matters: Reviews migraine pathogenesis and the mechanism-based therapies now changing clinical practice.

  2. medicalxpress.com63

    Physical activity weakens link between genetic risk and depression severity, long-term data suggest

    Researchers at the University of Texas at San Antonio analyzed data from 23,517 adults in the NIH All of Us Research Program, combining depression polygenic risk scores, electronic health records and long-term Fitbit measurements averaging about 1.6 years per participant. Published in Nature Mental Health, the study found greater physical activity was associated with lower depression severity, with a stronger association among those with higher genetic vulnerability. The team aims to use such findings to develop personalized exercise recommendations for depression prevention and management.

    Why it matters: Long-term wearable data show physical activity buffers genetic risk of depression severity, informing precision-medicine approaches.

  3. statnews.com60

    Americans trust science more than peers around the world, survey shows

    The Wellcome Global Monitor, a survey of more than 140,000 adults across 140 countries run with the Gallup World Poll, finds 52 percent of Americans report "a lot" of trust in science versus 26 percent globally. STAT's analysis shows the US is also more divided: a 24 percentage point gap between religious and non-religious Americans on whether science benefits most people, versus 5 points in other high-income nations, and a 19-point urban-rural gap. The growing divide stems from rising enthusiasm among college graduates and secular Americans rather than declining trust elsewhere.

    Why it matters: Documents US trust in science and vaccination attitudes from a 140-country survey, relevant to public health communication.

  4. thelancet.com58

    [The Lancet Commissions] The Lancet Commission on 21st century global threats to health

    The Lancet Commission on 21st century global health threats sets out a foresight-driven, health-focused method for identifying and prioritising major threats through the rest of the century. It points to recent shocks, including COVID-19, Ebola Bundibugyo virus disease, geopolitical conflict, climate change impacts, shifts in development assistance and powerful AI systems, as evidence that stability assumptions fail. It urges governments and multilateral institutions to replace short-termism with systematic, repeatable risk assessment and preparedness planning.

Oct 10Sat
  1. thelancet.com71

    [Lecture] 50 years of Ebola research and response

    Peter Piot and Jean-Jacques Muyembe-Tamfum delivered the two Virchow Prize Lectures in October 2026, covering 50 years of Ebola research and response. The lectures, published by The Lancet, trace the history of work on the disease. No further events are scheduled in the material.

    Why it matters: Two leading Ebola researchers reflect on five decades of research and response.

  2. medicalxpress.com65

    Tracking molecular malfunctions in metastatic colorectal cancer to find new avenues for treatment

    Hokkaido University researchers, working with an international team led by University of South Florida Health and Tampa General Hospital, have shown that the 30-year-old sphingolipid rheostat model operates in the tumor microenvironment rather than inside cancer cells in metastatic colorectal cancer. Analysis of 574 human colon cancer tissue samples showed that rising sphingosine-1-phosphate and falling long-chain ceramide create a biochemical barrier that excludes cytotoxic T cells. In lab experiments, blocking S1P/S1PR3 let killer T cells attack tumors again, pointing to a combination strategy with immunotherapy.

    Why it matters: It explains a mechanism of immunotherapy resistance in metastatic colorectal cancer and identifies a druggable pathway.

  3. statnews.com47

    STAT+: Pharma’s free lunches for doctors boost inappropriate prescribing, analysis finds

    A Cochrane review of dozens of previous studies found that gifts and payments doctors receive from drugmakers increased inappropriate prescribing and the number of prescriptions written, likely raising health care costs. Pharmaceutical advertising or education aimed at doctors may also increase inappropriate prescribing and prescription volumes. Conflict-of-interest policies restricting industry-doctor interactions probably improved prescribing, while evidence on free samples and formulary decisions was insufficient.

Oct 9Fri
  1. biopharmadive.com40

    This week in charts: What’s driving biotech’s recent pullback?

    The XBI biotech index, which nearly reached $170 a share in August after more than doubling in 12 months, has traded sideways since, weighed down by disappointing trial readouts, rising interest rates, midterm election worries and a slowdown in public company acquisitions. BioPharma Dive data show 26 private biotechs bought this year in deals of at least $50 million in guaranteed proceeds, versus 21 for public companies, with median startup acquisition value rising from $496 million in 2023 to $1 billion in 2026. Analysts expect caution to persist, though some investors see the XBI climbing again before the end of 2026.

  2. biocentury.com40

    After cardiovascular misses, developers rethink secondary prevention

    Cardiovascular drug developers are reassessing secondary prevention after a series of late-stage failures across IL-6, Lp(a), and Factor XI targets. The failed mechanisms all had substantial human genetic or biological support, exposing the difficulty of translating genetically validated biology into clinical benefit after decades of disease development. Companies including NewAmsterdam Pharma, Regeneron and Forbion are now under pressure to rethink trial design.

  3. medicalxpress.com51

    Common herbal sleep aid shows signs of addictive potential

    University of Connecticut researchers led by Steven Kinsey and Olivia Vanegas found that cannabinol (CBN), a cannabis-derived ingredient in over-the-counter sleep products, produced tolerance and withdrawal signs in mice given the compound twice daily for three days. Mice trained to recognize THC's effects responded identically to CBN, and CBN also weakened immune defense during a simulated bacterial challenge at non-psychoactive anti-inflammatory doses. The study appears in the November 2026 issue of Drug and Alcohol Dependence, and the authors say human research on dosing and long-term effects is still needed.

  4. medicalxpress.com55

    Pharmaceutical company marketing negatively influences prescribing

    A Cochrane review of 93 studies, led by Dr. Barbara Mintzes of the University of Sydney and Dr. Lisa Bero of the University of Colorado Anschutz, found that pharmaceutical industry marketing through sales visits, gifts, payments and free meals makes doctors' prescribing less appropriate, more frequent and more expensive. The review, published in the Cochrane Database of Systematic Reviews, showed a dose-response link between paid meals and prescribing, including increased opioid prescribing. Conflict-of-interest policies limiting industry contact may improve prescribing.

    Why it matters: Cochrane review quantifies how industry meals and gifts drive less appropriate, costlier prescribing across drug classes.

  5. nature.com40

    Daily briefing: Rogue ‘jumping genes’ age bigs dogs faster than little ones

    A study of nearly 900 dogs across about 120 breeds found that large dog breeds age faster than small ones, possibly because they carry more 'jumping genes' moving around their genomes. Ageing in dogs was accompanied by changes in chemical groups added onto DNA that control gene activity; these epigenetic changes accumulated faster in big dogs, and some appeared to let jumping genes disrupt normal genes.

  6. thelancet.com52

    [Comment] Deucrictibant: a novel oral on-demand treatment for hereditary angioedema

    A comment in The Lancet discusses deucrictibant, a novel oral on-demand treatment for hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH). The condition causes recurrent, unpredictable angioedema attacks that untreated can last 3–5 days and carry considerable morbidity and mortality, and the swelling does not respond to antihistamines, corticosteroids, or epinephrine. The piece examines an oral on-demand option for this setting.

  7. thelancet.com58

    [Correspondence] Bundibugyo virus: coordinating a cross-border response

    The Democratic Republic of the Congo and Uganda declared Ebola outbreaks caused by Bundibugyo virus on May 15, 2026, and the WHO Director-General declared a Public Health Emergency of International Concern on May 17, 2026. By Aug 26, 2026, 5815 confirmed cases and 2788 deaths had been reported, with 5794 cases and 2786 deaths in the Democratic Republic of the Congo across 60 health zones in six provinces. The correspondence addresses coordination of the cross-border response.

    Why it matters: Cross-border Bundibugyo Ebola outbreak declared a PHEIC with thousands of cases and deaths requires coordinated response.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org